Shintaro Izumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shintaro Izumi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Emiko Sakaida
Department of Hematology, Chiba University Hospital, Chiba, Japan
2 shared publications - Takayuki Hoshii
Kanazawa University, Kanazawa, Japan
2 shared publications Atsushi Kaneda
Chiba University Health and Disease Omics Center, Japan
1 shared publication- Atsushi Kaneda
Department of Molecular Oncology, Graduate School of Medicine, Chiba University
1 shared publication - Atsushi Okabe
Chiba University Graduate School of Medicine, Chiba, Japan
1 shared publication Ayako Arai
St. Marianna University School of Medicine, kawawsaki, Japan
1 shared publication
Latest Publications
- Open Access
- 2 September 2026
- Published by American Society of Hematology in Blood
Epstein-Barr virus-associated chromatin activation and enhancer engagement in T/NK-cell lymphoproliferative diseases
Epstein-Barr virus (EBV) infects many people and causes T-cell and natural killer (NK)-cell disorders, such as chronic active EBV disease and extranodal NK/T-cell lymphoma, which are aggressive and lack a common genetic driver. This suggests that virus-associated, non-genetic mechanisms contribute to disease. We studied primary T cells, NK cells, Epstein-Barr virus-positive cell lines derived from these disorders, virus-negative controls, and clinical chronic active EBV disease samples. Using genome-wide and single-cell multiome approaches, we examined three-dimensional chromatin organization, histone modifications, viral-host chromatin proximity, regulatory element activity, and transcription. EBV-positive lines shared a chromatin compartment pattern distinct from primary and virus-negative cancer cells. Regions that changed from inactive to active chromatin states showed increased activating histone marks and higher expression of nearby genes. EBV-interacting regions were enriched in inactive chromatin and inactive-to-active shifting regions, and contained activated promoters and enhancers associated with increased expression of neighboring genes in both T-cell and NK-cell backgrounds. Locus-level analyses identified CACNA2D1 and RGS1 as representative target genes with chromatin activation, and knockdown of each gene impaired cell growth in EBV-positive lines. Single-cell multiome profiling of clinical chronic active EBV disease samples identified EBV read-positive T-cell or NK-cell populations consistent with independently defined infected lineages and validated epigenomic and transcriptional rewiring at EBV-interacting regions. These findings support a model in which EBV contributes to oncogenic transcriptional programs in these diseases by coupling three-dimensional chromatin reorganization and regulatory element activation to physical interactions with the host genome.
- 2 September 2026
- Published by American Society of Hematology in Blood
Open AccessEpstein-Barr virus-associated chromatin activation and enhancer engagement in T/NK-cell lymphoproliferative diseases
Epstein-Barr virus (EBV) infects many people and causes T-cell and natural killer (NK)-cell disorders, such as chronic active EBV disease and extranodal NK/T-cell lymphoma, which are aggressive and lack a common genetic driver. This suggests that virus-associated, non-genetic mechanisms contribute to disease. We studied primary T cells, NK cells, Epstein-Barr virus-positive cell lines derived from these disorders, virus-negative controls, and clinical chronic active EBV disease samples. Using genome-wide and single-cell multiome approaches, we examined three-dimensional chromatin organization, histone modifications, viral-host chromatin proximity, regulatory element activity, and transcription. EBV-positive lines shared a chromatin compartment pattern distinct from primary and virus-negative cancer cells. Regions that changed from inactive to active chromatin states showed increased activating histone marks and higher expression of nearby genes. EBV-interacting regions were enriched in inactive chromatin and inactive-to-active shifting regions, and contained activated promoters and enhancers associated with increased expression of neighboring genes in both T-cell and NK-cell backgrounds. Locus-level analyses identified CACNA2D1 and RGS1 as representative target genes with chromatin activation, and knockdown of each gene impaired cell growth in EBV-positive lines. Single-cell multiome profiling of clinical chronic active EBV disease samples identified EBV read-positive T-cell or NK-cell populations consistent with independently defined infected lineages and validated epigenomic and transcriptional rewiring at EBV-interacting regions. These findings support a model in which EBV contributes to oncogenic transcriptional programs in these diseases by coupling three-dimensional chromatin reorganization and regulatory element activation to physical interactions with the host genome.
- Open Access
- 8 May 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (7) , 1627-1639
Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia
Histone H3 lysine 4 trimethylation (H3K4me3) is abundant in mixed-lineage leukemia-rearranged (MLL-r) acute myeloid leukemia (AML) cells; however, the responsible enzymes and their roles remain unclear. This study aimed to identify the modifier responsible for high H3K4me3 modification in MLL-r leukemia and its downstream targets essential for the cell proliferation. Here, we performed a CRISPR-tiling screen against known H3K4 methylation modifiers in an MLL-r AML model. Disrupting the SETD1B catalytic SET domain caused depletion of FLT3-ITD or NrasG12D-expressing AML cells, and gene expression downregulation, particularly in the MYC pathway. SETD1B SET domain loss results in a significant decrease in H3K4me3 breadth. Exogenous MYC expression or disrupting H3K4 demethylase KDM5C significantly restored growth defects in SETD1B SET domain-mutant cells. These data indicated that SETD1B was required for H3K4me3 breadth and MYC expression. Thus, a thorough understanding of SETD1B-mediated H3K4me3 breadth is critical for developing markers and therapies for MYC-dependent leukemia subtypes.
- 8 May 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (7) , 1627-1639
Open AccessRegulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia
Histone H3 lysine 4 trimethylation (H3K4me3) is abundant in mixed-lineage leukemia-rearranged (MLL-r) acute myeloid leukemia (AML) cells; however, the responsible enzymes and their roles remain unclear. This study aimed to identify the modifier responsible for high H3K4me3 modification in MLL-r leukemia and its downstream targets essential for the cell proliferation. Here, we performed a CRISPR-tiling screen against known H3K4 methylation modifiers in an MLL-r AML model. Disrupting the SETD1B catalytic SET domain caused depletion of FLT3-ITD or NrasG12D-expressing AML cells, and gene expression downregulation, particularly in the MYC pathway. SETD1B SET domain loss results in a significant decrease in H3K4me3 breadth. Exogenous MYC expression or disrupting H3K4 demethylase KDM5C significantly restored growth defects in SETD1B SET domain-mutant cells. These data indicated that SETD1B was required for H3K4me3 breadth and MYC expression. Thus, a thorough understanding of SETD1B-mediated H3K4me3 breadth is critical for developing markers and therapies for MYC-dependent leukemia subtypes.